Supplementary tables/figures:

Figure S1: Illustration of the steps involved in selection of eligible studies for this systematic



Supplementary Table S1: Key findings of miRNAs investigated singularly.

miRNAs	Author, Direction of dysregulation reported	Fold change OLK/OED vs N	Fold change OLK/OED vs OSCC	Fold change N vs OSCC	Fold change progressive OLK/OED vs Non progressive OLK/OED
miR 181c	(Yang *et al*., 2013) ↓	NS	NS	NS	↓15.40 (p<0.011)
miR 211	Check again for new data (excel sheet dated 7/2/21)				
miR 204-5p	(Philipone *et al*., 2016) ↑↓	NS	NS	NS	Progressive Vs non-progressive: 1.60 (p<0.250). ↓ in deep sequencing analysis and ↑ in progressive group in the validation set (Nss)
miR 222-3p	(Chang *et al*., 2018) ↓	↓ (p<0.0001)	NS	↓ (p<0.0001)	NS
miR 423-5p	(Chang *et al*., 2018) ↑	NS	↑in OSCC (p<0.001)	↑(p<0.001)	NS
miR 150-5p	(Chang *et al*., 2018) ↑	NS	↑in OSCC (p<0.001)	↑(p<0.001)	NS
miR-133b	(Cervigne *et al*., 2009) ↓	↓ 0.013 Nss (p=1)	NS	↓0.319 Nss (p=1)	NS
miR 494	(Harrandah *et al*., 2016) ↓	NS	↓ (0.015)	NS	NSD
miR 375	(Harrandah *et al*., 2016) ↓	NS	↓ (P=0.0001)	NS	↓ 8 (P=0.0004)
miR 208b-3p	(Philipone *et al*., 2016) ↑	NS	NS	NS	Progressive Vs Non-progressive: ↑1.73 (p<0.049)
miR 129-2-3p	(Philipone *et al*., 2016) ↓↑	NS	NS	NS	↓ in deep sequencing analysis and ↑ in validation set (Nss). Progressive Vs non-progressive: ↑1.36 (p<0.391)
miR 3065-5p	(Philipone *et al*., 2016) ↓	NS	NS	NS	↓0.86 in progressive group. (p<0.564)

miR 24	**(Prasad *et al*., 2017) ↓**	**CNRQ ratios: HNE/dysplasia ↓3.74 (p<0.05)**	**NS**	**CNRQ ratios: HNE/OSCC↓ 10.63 (P<0.05)**	**NS**
miR 26b	**(Prasad *et al*., 2017) ↓**	**CNRQ ratios: HNE/OED ↓ 7.23 (p<0.05)**	**CNRQ ratios: OSCC/OED ↓ 2.77 (P<0.05)**	**CNRQ ratios: HNE/OSCC ↓ 2.58 (P<0.05)**	**NS**
miR 155	**(Prasad *et al*., 2017) ↓**	**CNRQ ratios: HNE/OED ↓ 26.65 (P<0.05)**	**NS**	**CNRQ ratios: HNE/OSCC ↓ 8.67 (P<0.05)**	**NS**
miR 127	**(Prasad *et al*., 2017) ↑**	**CNRQ ratios: OED/HNE: ↑ 14.87 (P<0.05)**	**CNRQ ratios: OED/OSCC: ↑ 8.95 (P<0.05)**	**NS**	**NS**
miR 197	**(Prasad *et al*., 2017) ↑**	**NS**	**NS**	**NS**	**NS**
miR 197-3p	**(Yang *et al*. 2013) ↓**	**NS**	**NS**	**NS**	**↓16.89 (p<0.042)**
miR 210	**(Prasad *et al*., 2017) Unchanged**	**CNRQ Ratio – Unchanged (p>0.05)**	**NS**	**CNRQ Ratio – Unchanged (p>0.05)**	**NS**
miR 19b	**(Prasad *et al*., 2017) Unchanged**	**CNRQ Ratio – Unchanged (p>0.05)**	**NS**	**CNRQ Ratio – Unchanged (p>0.05)**	**NS**
miR 19a-3p	**(Yang *et al*., 2013) ↑**	**NS**	**NS**	**NS**	**↑9.24 (p<0.007)**
miR 205	**(Prasad *et al*., 2017) Unchanged**	**CNRQ Ratio – Unchanged (p>0.05)**	**NS**	**CNRQ Ratio – Unchanged (p>0.05)**	**NS**
miR 145	**(Zahran *et al*., 2015) ↓**	**With OED: ↓ (P<0.001) Without OED: ↓ (P<0.001)**	**With OED:0.6 (nss) Without OED: Nss**	**↓ (p<0.001)**	**NS**
miR 145-5p	**(Yang *et al*., 2013) ↓**	**NS**	**NS**	**NS**	**↓12.75 (p<0.01)**
miR 125a	**(Santhi *et al*., 2013) ↓**	**↓ 0.39 (mean qrt exp) (p<0.0001)**	**NS**	**↓0.23 (P<0.0001)**	**NS**
miR 125b-5p	**(Yang *et al*., 2013) ↓**	**NS**	**NS**	**NS**	**↓6.80 (p<0.01)**

miR 16	**(Santhi *et al*., 2013) ↓**	**↓0.6 (p<0.0001)**	**NS**	**↓0.38 (P<0.0001)**	**NS**
miR 96	**(Santhi *et al*., 2013) ↑**	**↑5.42 (p<0.0001)**	**NS**	**↑78.64 (P<0.0001)**	**NS**
miR 129-5p	**(Chen *et al*., 2018) ↓**	**NSD**	**OLK-OSCC vs OLK : ↓ (p=0.0041)**	**OLK-OSCC vs N : ↓ (p=0.0001)**	**NS**
miR 296-5p	**(Chen *et al*., 2018) ↓**	**NSD**	**OLK-OSCC vs OLK : ↓ (p=0.0014)**	**OLK-OSCC vs N : ↓ (p=0.0002)**	**NS**
miR 450b-5p	**(Chen *et al*., 2018) ↑**	**Normal vs OLK: ↓ (p=0.046)**	**OLK-OSCC vs OLK : ↑ (p=0.0007)**	**OLK-OSCC vs N: ↑ (p=0.0001)**	**NS**
miR196b	**(Lu *et al*., 2015) ↑**	**↑14.8 (p<0.01)** **OR 46.2 (P<0.0001)**	**NS**	**↑17.0 (p<0.0001)** **OR 189 (P<0.0001)**	**NS**
miR 146b	**(Cervigne *et al*., 2009) ↑**	**NS**	**NS**	**NS**	**↑**
miR 372	**(Kao *et al*., 2015) ↑↓**	**↑**	**NS**	**↓**	**NS**
let 7i	**(Kao *et al*., 2015) ↑↓**	**↓**	**NS**	**↑**	**NS**
let 7a-5p	**(Yang *et al*., 2013) ↓**	**NS**	**NS**	**NS**	**↓5.74 (p<0.039)**
miR 10b-5p	**(Yang *et al*., 2013) ↑**	**NS**	**NS**	**NS**	**↑ 11.51 (p<0.008)**
miR 99a-5p	**(Yang *et al*., 2013) ↓**	**NS**	**NS**	**NS**	**↓ 6.8 (p<0.011)**
miR 99b-5p	**(Yang *et al*., 2013) ↓**	**NS**	**NS**	**NS**	**↓18.75(p<0.003)**
miR 100-5p	**(Yang *et al*., 2013) ↓**	**NS**	**NS**	**NS**	**↓8.33 (p<0.01)**
miR 331-3p	**(Yang *et al*., 2013) ↓**	**NS**	**NS**	**NS**	**↓6.84 (p<0.01)**
miR 15a-5p	**(Yang *et al*., 2013) ↓**	**NS**	**NS**	**NS**	**↓12.51 (p<0.002)**
miR 708	**(Yang *et al*., 2013) ↑**	**NS**	**NS**	**NS**	**↑11.89 (p<0.014)**
miR 150-5p	**(Yang *et al*., 2013) ↓**	**NS**	**NS**	**NS**	**↓5.63 (p<0.002)**
miR 30e-3p	**(Yang *et al*., 2013) ↑**	**NS**	**NS**	**NS**	**↑20.41 (p<0.002)**
miR 30a-3p	**(Yang *et al*., 2013) ↑**	**NS**	**NS**	**NS**	**↑3.80 (p<0.049)**
miR 335-5p	**(Yang *et al*., 2013) ↑**	**NS**	**NS**	**NS**	**↑2.08 (p<0.039)**
miR 144*	**(Yang *et al*., 2013) ↑**	**NS**	**NS**	**NS**	**↑12.22 (p<0.005)**
miR 25-3p	**(Yang *et al*., 2013) ↑**	**NS**	**NS**	**NS**	**↑12.88 (p<0.017)**
miR 660-5p	**(Yang *et al*., 2013) ↑**	**NS**	**NS**	**NS**	**↑27.92 (p<0.02)**
miR 140-5p	**(Yang *et al*., 2013) ↑**	**NS**	**NS**	**NS**	**↑16.23 (p<0.012)**
miR 590-5p	**(Yang *et al*., 2013) ↑**	**NS**	**NS**	**NS**	**↑15.79 (p<0.004)**

miR-17-5p	**(Cervigne *et al*., 2009) ↓**	**↓0.351 Nss (p=0.98)**	**NS**	**↓0.644 Nss (p=0.97)**	**NS**
miR-106b	**(Cervigne *et al*., 2009) ↑**	**↑ 1.157 (p=0.067)**	**NS**	**↑1.134 (P=0.054)**	**NS**
miR-518b	**(Cervigne *et al*., 2009) ↑**	**↑2.557 (P<0.01)**	**NS**	**↑3.076 (p<0.01)**	**↑ in progressive**
miR-520g	**(Cervigne *et al*., 2009) ↑**	**↑2.57 (P<0.01)**	**NS**	**↑9.932 (P<0.01)**	**↑ in progressive**
miR-649	**(Cervigne *et al*., 2009) ↑**	**↑3.77 (P<0.01)**	**NS**	**↑3.464 (P<0.01)**	**↑ in progressive**

OSCC: Oral Squamous Cell Carcinoma; N: normal mucosa; OLK: Oral Leukoplakia; OED: Oral Epithelial Dysplaisa; NS- not specified; NSS- not statistically significant;

OPMD: Oral Potentially Malignant Disorders; NSD: No significant difference.